[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634096":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":11,"locations":10,"responsibleParty":17,"collaborators":10,"id":20,"slug":21,"hasResults":22,"nctId":23,"briefTitle":24,"officialTitle":25,"acronym":10,"eligibilityCriteria":26,"healthyVolunteers":22,"sex":27,"minAge":28,"maxAge":29,"enrollmentInfo":30,"targetDuration":10,"studyType":33,"phases":10,"briefSummary":34,"conditions":35,"keywords":10,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":10},{"fullName":5,"class":6},"Ondokuz Mayıs University","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":10},"Progressive Multiple Sclerosis",null,[12],{"name":13,"role":14,"phone":15,"phoneExt":10,"email":16},"Seda Nur Kemer","CONTACT","+903623121919","sedakemer@gmail.com",{"type":18,"investigatorFullName":13,"investigatorTitle":19,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Lecturer, Department of Physiotherapy and Rehabilitation","100634096","serum-gfap-nfl-vegf-and-clinical-progression-in-progressive-ms-100634096",false,"NCT07535242","Serum GFAP, NfL, VEGF and Clinical Progression in Progressive MS","Investigation of the Relationship Between Serum GFAP, NfL, and VEGF Levels and Clinical Progression Markers in Progressive Multiple Sclerosis","Inclusion Criteria:\n\n* Confirmed diagnosis of MS\n* Progressive type MS\n* Voluntary participation\n* Age between 18-60 years\n* Cooperative\n* EDSS score ≥ 5.5\n\nExclusion Criteria:\n\n* Presence of another neurological disorder\n* Change in medication within the last 3 months\n* Relapse within the last 3 months","ALL","18 Years","60 Years",{"count":31,"type":32},22,"ESTIMATED","OBSERVATIONAL","This study aimed to investigate whether the biomarkers GFAP, NfL, and VEGF-recently considered important guides for better understanding the pathophysiology of MS-also serve as indicators of clinical progression in MS.",[36],"Multiple Sclerosis","NOT_YET_RECRUITING","2026-04-14",{"date":40,"type":41},"2026-04-17","ACTUAL",{"date":43,"type":32},"2026-04-21",{"date":45,"type":32},"2026-05-05",{"name":5,"class":6}]